RV-EnVA-△G-ChR2-dsRed [Rabies Virus (RABV)]
Combined with AAV-TVA and AAV-RVG, Retrograde, Monosynaptic
Through reverse genetics, a recombinant RABV constructed by Wickersham et al. Based on the SAD-B23 vaccine strain. The glycoprotein gene of modified RABV is completely removed (G deletion) and loses the ability to cross synapses, but its replication and transcription are not affected. RABV-∆G can be used to reverse high-brightness and finely labeled neurons. If we provide G protein first (inject AAV-G first), then the recombinant RABV will have the ability to propagate retrograde in the synapse.
In order to further improve the targeting effect of G-deficient RABV on specific starting cells, the virus was modified by binding to the envelope protein EnvA of avian sarcoma and leukemia virus (ASLV). The infectivity of these viruses is limited to cells that carry TVA receptors. Of course, the receptor TVA and EnvA proteins must be provided first.
After years of research, Creative Biolabs has established a stable production platform and can provide rabies virus (RABV) services to promote RABV-based neuron tracking research.
●Changes in neural networks during neural development
●Single synapse tracking of specific types of neurons
2. Osakada F, Callaway EM. Design and generation of recombinant rabies virus vectors. Nat Protoc. 2013 Aug;8(8):1583-601.
3. Callaway EM, Luo L. Monosynaptic Circuit Tracing with Glycoprotein-Deleted Rabies Viruses. J Neurosci. 2015 Jun 17;35(24):8979-85.